Advertisements



We are Sorry, This Page doesn't Exist


Weston company secures $10M in funding for drug to treat rare kidney disease

Incon Co., a publicly traded South Korean biotech investor, has given Weston-based Variant Pharmaceuticals $10 million in financing in exchange for equity ownership. The funding will be used to develop VAR 200 for the treatment of rare kidney disease .....»»

Category: topSource: bizjournalsDec 4th, 2018

Biogen tanks as Alzheimer"s drug results disappoint

The experimental treatment slowed the disease, but not enough to meet investors' high expectations.....»»

Category: topSource: moneycentralJul 26th, 2018

Cambridge biotech startup grabs $65M to tackle liver disease

A newly launched biotech company has secured $65 million in financing as it seeks to develop the first-ever treatment for a disorder that its co-founder described as “the life being squeezed out of the liver.” Cambridge-based Akero Therapeutics is fo.....»»

Category: topSource: bizjournalsJun 25th, 2018

Alzheimer’s Disease Symptoms Reversed in Flies by Balancing Enzymes

This finding could pave the wave for Alzheimer's treatment and biomarkers for early diagnosis......»»

Category: topSource: newsweekMay 15th, 2018

IPO News This Week: Two Solid Offerings on Tap

The two IPOs on this week's calendar include one tech unicorn and a biotech working on a treatment from Alzheimer disease......»»

Category: blogSource: 247wallstApr 8th, 2018

BioArctic - Full Year Report January - December 2018

STOCKHOLM, Feb. 14, 2019 /PRNewswire/ -- BioArctic's partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer's disease. AbbVie in-licensed the Parkinson po.....»»

Category: earningsSource: benzingaFeb 14th, 2019

Coty and Electronic Arts surge while Molson Coors dips

Stocks that moved substantially or traded heavily on Tuesday: Gilead Sciences Inc., down $2.22 to $65.40 A potential liver disease under development by the biotechnology company failed to meet its treatment goal in a key study......»»

Category: topSource: foxnewsFeb 12th, 2019

Exclusive: Quietly, Gladstone founder"s new company plots unique attack on Alzheimer"s

In stealth mode, GABAeron is one of a growing number of companies zeroing in on new ways to stall, stop or cure Alzheimer's disease......»»

Category: topSource: bizjournalsFeb 6th, 2019

GSK, Merck KGaA partner to jointly develop cancer treatment M7824

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 5th, 2019

Gwyneth Paltrow and Netflix Sign Deal on Goop Docuseries

The show is set to premiere in the fall. Goop is getting the Netflix treatment. According to Variety, the lifestyle and wellness brand founded by actress Gwyneth Paltrow in 2008 is partnering with Netflix to develop a new docus.....»»

Category: europeSource: fortuneFeb 4th, 2019

MeiraGTx partnering with Janssen to develop and market retinal disease therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 31st, 2019

The Daily Biotech Pulse: Roche Scraps Alzheimer"s Disease Trials, Amgen Issues Weak Guidance

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 29) read more.....»»

Category: blogSource: benzingaJan 30th, 2019

The Daily Biotech Pulse: Roche Scraps Alzheimer"s Disease Trials, Amgen Issues Weak Guidance

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The P.....»»

Category: earningsSource: benzingaJan 30th, 2019

New research found a link between Alzheimer"s and gum disease bacteria, but there are other reasons gum disease is bad for your health

Jeff J Mitchell/Getty Images A new study found a .....»»

Category: topSource: businessinsiderJan 25th, 2019

Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year

Non-alcoholic fatty liver disease, or NAFLD, is a disorder resulting from accumulation o.....»»

Category: blogSource: benzingaJan 18th, 2019

Could This Radical New Approach to Alzheimer’s Lead to a Breakthrough?

In a small lab in Jackson Hole, Wyo., 65-year-old Paul Cox believes he’s closing in on a treatment that might prevent Alzheimer’s disease. And ALS. And a host of other .....»»

Category: europeSource: fortuneJan 18th, 2019

Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data

Omeros Corporation (NASDAQ: OMER) shares are seeing buying interest Thursday following a clinical update on its lead human monoclonal antibody OMS721, which is being evaluated for IgA nephropathy. read more.....»»

Category: blogSource: benzingaJan 17th, 2019

Ultragenyx Wins Big in Blood Sugar Study

Ultragenyx Pharma shares made a handy gain to close out the week after the company announced positive results from its midstage trial for the treatment of glycogen storage disease type Ia......»»

Category: blogSource: 247wallstJan 4th, 2019

A new type of breast cancer treatment could help stop the spread of a highly aggressive form of the disease

Eric Gaillard/Reut.....»»

Category: topSource: businessinsiderJan 4th, 2019

Biogen doubles down on Alzheimer"s with new collaboration deal

On the eve of biotech's biggest conference, Biogen has announced two drug development deals — worth up to almost $500 million combined — targeting Alzheimer's disease and other neurological disorders. Biogen (Nasdaq: BIIB) said Friday that i.....»»

Category: topSource: bizjournalsJan 4th, 2019